AAA signs agreement with FUJIFILM Toyama Chemical to develop FF-10158 for oncology

(Advanced Accelerator Applications) Advanced Accelerator Applications S.A. (AAA), a Novartis company and leader in nuclear medicine theragnostics, today announced that it has entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical, a leading radiopharmaceutical company in Japan, to develop and commercialize radiolabeled FF-10158 for oncology indications. Under the terms of the agreement, AAA is granted worldwide rights to FF-10158, with the exception of Japan, in exchange for an upfront payment and future milestones and royalties.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news